Anemic Myelofibrosis | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Anemic Myelofibrosis (MF) is clonal disease of hematopoietic stem cells characterized by abnormal myeloproliferation and abnormal cytokine production, leading to progressive fibrosis, inflammation, and functional impairment of the bone marrow niche. Anemia is a common and distressing clinical manifestation of myelofibrosis (MF) of complex etiology. Myelofibrosis is a rare disease with an annual incidence of approximately 0.5-1.5 cases per year. 100,000 people in the United States. In a review of European data sources, the incidence of myelofibrosis (myelofibrosis) was between 0.1 and 1. 100,000 cases per year. Patients with myelofibrosis receiving ruxolitinib may require dose reduction, discontinuation, or early discontinuation of therapy, which may reduce the effectiveness of therapy or reduce red blood cell transfusions throughout therapy.

Description

Anemic Myelofibrosis (MF) is a clonal disease of hematopoietic stem cells that is characterized by abnormal myeloproliferation and abnormal cytokine production, resulting in progressive fibrosis, inflammation, and functional impairment of the bone marrow niche. Myelofibrosis (MF), which has a complex etiology, frequently exhibits the distressing clinical symptom of anemia. Within a year of being diagnosed, the majority of myelofibrosis patients experience anemia, and all require red blood cell transfusions over time. Lesser health-related quality of life (HRQoL) and shorter survival are linked to anemia. Splenomegaly, hypercatabolic symptoms, and anemia are all symptoms of myelofibrosis, which is characterized by extramedullary hematopoiesis, failure of the bone marrow, and abnormalities of the spleen. Allogeneic hematopoietic stem cell transplantation (ASCT), which is only available to a small% of myelofibrosis patients, is still a viable option for the treatment of the disease. The standard clinical MF risk scoring systems also included anemia and transfusion dependency as independent negative predictors.

Anemic Myelofibrosis (Epidemiology)

Myelofibrosis is a rare disease with an annual incidence of approximately 0.5-1.5 cases per year. 100,000 people in the United States. In a review of European data sources, the incidence of myelofibrosis (myelofibrosis) was between 0.1 and 1. 100,000 cases per year. The incidence of primary myelofibrosis appears to be higher in eggs than in people of other races. Additionally, Ashkenazi Jews exhibit a high incidence of this illness. However, in younger children, girls are twice as likely as boys to have primary myelofibrosis. The average age at diagnosis for primary myelofibrosis, also known as myelofibrosis, is about 65 years old. However, cases of the illness have been documented in people of all ages, from newborns to those who are 80 years old. Patients under the age of 56 make up about 22% of those who are affected. Children who develop primary myelofibrosis typically do so within the first three years of life.

Anemic Myelofibrosis -Current Market Size & Forecast Trends

The market for anemic myelofibrosis is projected to grow steadily, with estimates indicating a value of approximately USD 749.05 million in 2023, expected to reach around USD 1.28 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% during this period. This growth is driven by the increasing prevalence of myelofibrosis, advancements in treatment options including JAK inhibitors, and rising awareness of the condition. The market for anemic myelofibrosis is well-positioned for gradual growth through 2035 as new therapies and treatment strategies continue to emerge.

Ruxolitinib therapy for myelofibrosis patients may need to be reduced in dose, stopped altogether, or stopped early. These actions could lessen the effectiveness of the medication or cut down on the number of times the patient needs to receive transfusions of red blood cells. 50% of myelofibrosis patients received ruxolitinib in addition to androgens, corticosteroids, or erythropoietic drugs to treat anemia. The average length of ruxolitinib treatment in the real world was shorter than in clinical trials, despite the use of supportive measures. Although there may be a number of factors influencing this short-term therapy, evidence points to side effects (such as anemia) and a diminished response to therapy as two significant ones. The development of therapies that specifically address anemia and other myelofibrosis symptoms may enhance patient outcomes. Momelotinib inhibits ACVR1/ALK2 and JAK1 and JAK2 to increase serum iron availability for erythropoiesis. Hepcidin is a crucial regulator of elevated iron metabolism in myelofibrosis patients. Momotinib has been shown in phase III studies to decrease anemia rates, dependence on blood transfusions, spleen size, and symptoms, so Sureau et al. Additionally, a number of combination therapies, such as ruxolitinib plus luspatercept, activin receptor ligand trap/erythrocyte maturation agent, ruxolitinib Niga pelaresib, and bromodomains, are currently undergoing clinical trials and have demonstrated clinical activity against anemia and other markers of MF. A B-cell lymphoma protein antigen (BCL-XL, BCL-2, BCL-w) along with the (BET) inhibitor ruxolitinib and navitoclax.

Report Highlights

Anemic Myelofibrosis - Current Market Trends

Anemic Myelofibrosis - Current & Forecasted Cases across the G8 Countries

Anemic Myelofibrosis - Market Opportunities and Sales Potential for Agents

Anemic Myelofibrosis - Patient-based Market Forecast to 2035

Anemic Myelofibrosis - Untapped Business Opportunities

Anemic Myelofibrosis - Product Positioning Vis-a-vis Competitors' Products

Anemic Myelofibrosis - KOLs Insight